アスペルギルス症の世界市場-2023年～2030年

概要

世界のアスペルギルス症市場は、2022年に32億米ドルに達し、2023～2030年の予測期間中にCAGR 5.6％で成長し、2030年には65億米ドルに達すると予測されます。

世界的に、アスペルギルス症の有病率は、がん治療、臓器移植、長期にわたる免疫抑制療法による免疫不全集団の割合の上昇に伴う先進医療の市場発展の結果として増加しており、アスペルギルス症市場が予測期間中に成長するのに役立ちます。

アスペルギルス症は、通常、下気道を侵す日和見感染症であり、環境中に一般的に存在する糸状菌アスペルギルスの芽胞を吸い込むことによって引き起こされます。芽胞は発芽して菌糸となり、血管内に侵入し、侵襲性疾患では出血性壊死および梗塞を引き起こします。症状は、喘息、肺炎、副鼻腔炎、あるいは急速に進行する全身性疾患です。

さらに、世界のアスペルギルス症市場は、医療費の増加、製品パイプラインの充実、真菌感染症の有病率の増加、医療従事者や一般住民の間での疾患に対する意識の高まり、診断技術の進歩など、新しく改良された治療法を導入するための研究開発の増加といった様々な要因によって牽引されます。

ダイナミクス

アスペルギルス症の有病率の上昇

アスペルギルス症の有病率の上昇は、予測期間中に市場が成長するための重要な主要な要因の1つです。アスペルギルス症はあらゆる年齢層の個人を罹患させ、特に脆弱な集団に深刻な結果をもたらします。アスペルギルス症は、免疫系が弱っている人の間でより一般的です。

例えば、ミネソタ大学が発表した「インドにおける重篤な真菌感染症の負担」に関する最新の研究によると、アスペルギルス症の年間罹患率は1.5％です。慢性肺アスペルギルス症の年間発生率は推定212,502例で、診断後1年間の死亡者数は42,766人です。慢性肺アスペルギルス症の負荷の約90％は肺結核と関連しており、著者らは総有病率は約170万例と推定しています。

進行中の臨床試験数の増加

進行中の臨床試験の増加は、予測期間中に市場が成長するための重要な要因の1つです。現在、様々な研究機関や研究産業などが実施中の臨床試験があります。例えば、2022年3月のclinicaltrails.govによると、Olorofim Aspergillus Infection Study（OASIS）と題された研究が記録されており、この研究の目的は、証明されたIAまたは可能性の高い下気道疾患アスペルギルス種（侵襲性アスペルギルス症、IA）に起因するIFD患者において、オロロフィムによる治療とアムビゾームによる治療、それに続く標準治療（SOC）を比較することでした。したがって、これらの試験は2025年3月までに完了すると推定されます。

さらに、clinicaltrails.govによると、Merck Sharp &Dohme LLCが実施している侵襲性アスペルギルス症（IA）を有する小児におけるポサコナゾール静注および経口に関する別の進行中の試験があります。この試験の目的は、侵襲性アスペルギルス症（IA）を有する2～18歳未満の小児参加者を対象に、ポサコナゾール（POS）静注製剤および経口製剤の安全性、有効性および薬物動態を評価することであり、この試験は2024年4月までに完了する予定です。

アスペルギルス症に伴う合併症

感染症の種類によっては、アスペルギルス症は様々な重篤な合併症を引き起こす可能性があり、予測期間中の市場成長を妨げる欠点要因として作用します。そのうちのいくつかは出血です。アスペルギローマも侵襲性アスペルギルス症も、肺に重篤な、時には致命的な出血を引き起こす可能性があります。全身感染は、侵襲性アスペルギルス症の最も重篤な合併症で、体の他の部位、特に脳、心臓、腎臓への感染の拡大です。侵襲性アスペルギルス症は急速に拡大し、命に関わることもあります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • アスペルギルス症の有病率の上昇
    • 進行中の臨床試験数の増加
  • 抑制要因
    • アスペルギルス症に伴う合併症
  • 機会
    • 強固な製品パイプラインの増加
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• ロシア・ウクライナ戦争の影響分析
• DMIの見解

第6章 COVID-19分析

第7章 タイプ別

• 慢性肺アスペルギルス症
• アレルギー性気管支肺アスペルギルス症（ABPA）
• 侵襲性アスペルギルス症

第8章 薬剤タイプ別

• イサブコナゾール
• ボリコナゾール
• アムホテリシン-B
• イトラコナゾール
• コルチコステロイド
• ポサコナゾール
• その他

第9章 投与経路別

• 経口
• 静脈内

第10章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第11章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋
• 中東・アフリカ

第12章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第13章 企業プロファイル

• Pfizer
  • 企業概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な動向
• Therma Fisher Scientific
• Rewine Pharmaceuticals
• Teva Pharmaceuticals
• Eugia Pharma
• krishlar Pharmaceuticals
• Merck
• Aozeal
• Hikma
• Xellia Pharmaceuticals

第14章 付録

Overview

Global Aspergillosis Market reached US$ 3.2 billion in 2022 and is expected to reach US$ 6.5 billion by 2030, growing with a CAGR of 5.6% during the forecast period 2023-2030.

Globally, the prevalence of aspergillosis is increasing as a result of the development of advanced medical practices with a rise in the proportion of immunocompromised populations due to cancer treatment, organ transplantation, and prolonged immunosuppressive therapy helps the Aspergillosis market to grow during the forecast period.

Aspergillosis is an opportunistic infection that usually affects the lower respiratory tract and is caused by inhaling spores of the filamentous fungus Aspergillus, commonly present in the environment. The spores germinate and develop into hyphae, which enter blood vessels and, with invasive disease, cause haemorrhagic necrosis and infarction. Symptoms may be those of asthma, pneumonia, sinusitis, or rapidly progressing systemic illness.

Furthermore, the global aspergillosis market is driven by various factors like a rise in research and development to introduce new and improved treatment options increasing healthcare expenditure, robust product pipeline, rise in increasing prevalence of fungal infections, rising awareness about the disease among healthcare professionals and the general population, and advancements in diagnostic techniques are primary growth drivers for the aspergillosis treatment market.

Dynamics

Rise in the Prevalence of Aspergillosis

The rise in the prevalence of aspergillosis is one of the significant key factors that help the market to grow during the forecast period. Aspergillosis affects individuals of all ages and has severe consequences, particularly in vulnerable populations. Aspergillosis is more common among individuals with weakened immune systems.

For instance, according to the University of Minnesota updated study published on the Burden of serious fungal infections in India. The annual incidence of chronic pulmonary aspergillosis is an estimated 212,502 cases, including 42,766 deaths in the year following diagnosis. About 90% of the chronic pulmonary aspergillosis burden is associated with pulmonary tuberculosis, and the authors estimate that the total prevalence is about 1.7 million cases.

Rise in Number of Ongoing Clinical Trails

The rise in ongoing clinical trials is one of the key factors that helps the market to grow during the forecast period. There are currently ongoing clinical trials which are conducted by various institutes, research industries and others. For instance, according to clinicaltrails.gov in March 2022, there was a study which is recorded titled Olorofim Aspergillus Infection Study (OASIS) where the objective of this study was to compare treatment with olorofim versus treatment with AmBisome followed by standard of care (SOC) in patients with IFD caused by proven IA or probable lower respiratory tract disease Aspergillus species (invasive aspergillosis, IA. Hence, these studies are estimated to be complete by March 2025.

Additionally, according to clinicaltrails.gov another ongoing study on Posaconazole Intravenous and Oral in Children With Invasive Aspergillosis (IA) which is conducted by Merck Sharp & Dohme LLC where the study objective is to evaluate the safety, efficacy, and pharmacokinetics of Posaconazole (POS) intravenous (IV) and oral formulations in pediatric participants 2 to <18 years of age with invasive aspergillosis (IA) and this studies are expected to complete by April 2024.

Complications Associated with Aspergillosis

Depending on the type of infection, aspergillosis can cause a variety of serious complications which act as a drawback factor that hamper the market growth during the forecast period. Some of them are Bleeding. Both aspergillomas and invasive aspergillosis can cause severe, and sometimes fatal, bleeding in your lungs. Systemic infection. The most serious complication of invasive aspergillosis is the spread of the infection to other parts of your body, especially your brain, heart and kidneys. Invasive aspergillosis spreads rapidly and may be fatal.

Segment Analysis

The global Aspergillosis market is segmented based on type, drug type, route of administration, distribution channel and region.

The Isavuconazole Segment From the Drug Type Segment Accounted For Approximately 41.7% of Aspergillosis Share

The isavuconazole segment from the drug type segment accounted for 41.7% and it is expected to be dominated during the forecast period. Isavuconazole is the newest of the clinically available advanced-generation triazole antifungals and is active against a variety of yeasts, moulds, and dimorphic fungi. Its current FDA-approved indications include the management of invasive aspergillosis as well as mucormycosis, though the latter indication is supported by limited clinical data

For instance, Basilea Pharmaceutica Ltd, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases and cancer, announced that its license partner, Pfizer Inc., has received a drug approval license from the National Medical Products Administration (NMPA) in China, for the oral formulation of its antifungal Cresemba (isavuconazole) for the treatment of adult patients with invasive aspergillosis.

Geographical Penetration

North America Accounted for Approximately 38.4% of the Market Share

North America is estimated to hold about 38.4 % of the total market share throughout the forecast period, owing to the factors like FDA approvals, new product launches, rise in the healthcare infrastructure, and rising clinical trials by various institutes and research industries help this region to grow during the forecast period.

For instance, in August 2023 Astellas Pharma US, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) for CRESEMBA (isavuconazonium sulfate), a prodrug of isavuconazole, an azole antifungal drug, seeking approval for the treatment of invasive aspergillosis (IA) or invasive mucormycosis (IM) in pediatric patients aged one to 17 years old. Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date of December 9, 2023.

Competitive Landscape

The major global players in the market include: Pfizer, Therma Fisher Scientific, Rewine Pharmaceuticals, Teva Pharmaceuticals, Eugia Pharma, krishlar Pharmaceuticals, Merck, Aozeal, Hikma, Xellia Pharmaceuticals and among others.

COVID-19 Impact Analysis

COVID-19 had a substantial impact on the global Aspergillosis market which damaged the lining of airways from severe SARS-CoV-2 infection allows Aspergillus fungi to invade the tissue, according to a recent consensus guidance from the European Confederation of Medical Mycology and the International Society for Human and Animal Mycology. These secondary fungal infections can worsen patient outcomes, and they've raised concern about emerging evidence of Aspergillus resistance to voriconazole and isavuconazole, the first-line therapies.

The coronavirus (COVID-19) pandemic also had a substantial impact on the development, production, and supply of pharmaceutical products and affected the growth of the medication used in the treatment of chronic aspergillosis such as antifungal drugs and corticosteroids manufactured by various companies across the regions such as North America, Europe, and Asia Pacific.

By Type

• Chronic Pulmonary Aspergillosis
• Allergic Bronchopulmonary Aspergillosis (ABPA)
• Invasive Aspergillosis

• Invasive Fungal Rhinosinusitis
• Invasive Pulmonary Aspergillosis

By Drug Type

• Isavuconazole
• Voriconazole
• Amphotericin-B
• Itraconazole
• Corticosteroids
• Posaconazole
• Others

By Route of Administration

• Oral
• Intravenous

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • UK
  • France
  • Italy
  • Russia
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• In June 2023, Endo International plc announced that its Par Sterile Products business has begun shipping posaconazole injection (18 mg/mL), the first generic version of Merck's Noxafil in the U.S., following final approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application. Posaconazole injection is indicated for prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections.
• In February 2023, Pulmatrix, Inc. a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE technology, announced the first patient dosed in a Phase 2b trial evaluating the safety and efficacy of PUR1900 in subjects with Allergic Bronchopulmonary Aspergillosis (ABPA) and asthma. PUR1900 is the company's iSPERSE-enabled dry powder formulation of itraconazole, developed for inhaled pulmonary delivery.
• In December 2022 Asahi Kasei Pharma obtained approval to manufacture and sell Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg (generic name: isavuconazonium sulfate, development) in Japan for treatment of the fungal infections of aspergillosis, mucormycosis, and cryptococcosis.

Why Purchase the Report?

• To visualize the global Aspergillosis market segmentation based on type, drug type, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global Aspergillosis market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The Global Aspergillosis Market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Drug Type
• 3.3. Snippet by Route of Administration
• 3.4. Snippet by Distribution Channel
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rise in the Prevalence of Aspergillosis
    • 4.1.1.2. Rise in Number of Ongoing Clinical Trails
  • 4.1.2. Restraints
    • 4.1.2.1. Complications associated with Aspergillosis
  • 4.1.3. Opportunity
    • 4.1.3.1. Rise in Robust Product Pipeline
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Russia-Ukraine War Impact Analysis
• 5.6. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type
• 7.2. Chronic Pulmonary Aspergillosis*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Allergic Bronchopulmonary Aspergillosis (ABPA)
• 7.4. Invasive Aspergillosis

8. By Drug Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 8.1.2. Market Attractiveness Index, By Drug Type
• 8.2. Isavuconazole*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Voriconazole
• 8.4. Amphotericin-B
• 8.5. Itraconazole
• 8.6. Corticosteroids
• 8.7. Posaconazole
• 8.8. Others

9. By Route of Administration

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.1.2. Market Attractiveness Index, By Route of Administration
• 9.2. Oral *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Intravenous

10. By Distribution Channel

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.1.2. Market Attractiveness Index, By Distribution Channel
• 10.2. Hospital Pharmacies *
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Retail Pharmacies
• 10.4. Online Pharmacies

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.7.1. U.S.
    • 11.2.7.2. Canada
    • 11.2.7.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.7.1. Germany
    • 11.3.7.2. UK
    • 11.3.7.3. France
    • 11.3.7.4. Italy
    • 11.3.7.5. Spain
    • 11.3.7.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.7.1. Brazil
    • 11.4.7.2. Argentina
    • 11.4.7.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.7.1. China
    • 11.5.7.2. India
    • 11.5.7.3. Japan
    • 11.5.7.4. Australia
    • 11.5.7.5. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

• 13.1. Pfizer *
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Financial Overview
  • 13.1.4. Key Developments
• 13.2. Therma Fisher Scientific
• 13.3. Rewine Pharmaceuticals
• 13.4. Teva Pharmaceuticals
• 13.5. Eugia Pharma
• 13.6. krishlar Pharmaceuticals
• 13.7. Merck
• 13.8. Aozeal
• 13.9. Hikma
• 13.10. Xellia Pharmaceuticals

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us